Physician profile
David Petkus
NPI 1740878669
$11,289.52
in general payments reported to CMS, 2019-2025
26 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,056 · 2022: $3,551 · 2023: $4,006 · 2024: $1,562 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,633 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,633.42 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,282.58 | 2021-2024 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $1,206.77 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,166.23 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,156.74 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $1,086.54 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $754.21 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Braeburn INC. | $748.37 | 2023-2025 | Brixadi |
| Neurocrine Biosciences, INC. | $720.48 | 2021-2024 | Ingrezza |
| Indivior INC. | $636.42 | 2022-2025 | Sublocade, Perseris |
| Ironshore Pharmaceuticals INC. | $580.89 | 2021-2023 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $445.31 | 2022-2023 | Austedo Xr, Austedo |
| Lundbeck LLC | $306.77 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $271.99 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $261.75 | 2022-2023 | Auvelity |
| Merck Sharp & Dohme LLC | $128.03 | 2021-2023 | Belsomra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $121.86 | 2021-2022 | |
| Corium, LLC | $81.74 | 2022-2023 | Azstarys |
| Novo Nordisk INC | $77.85 | 2023 | Ozempic, Rybelsus, Wegovy |
| Vanda Pharmaceuticals INC. | $70.39 | 2022-2023 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $44.58 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $36.15 | 2021 | |
| Eisai INC. | $33.55 | 2021 | |
| Paratek Pharmaceuticals, INC. | $21.17 | 2024 | Nuzyra |
| Biohaven Pharmaceuticals, INC. | $18.94 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.76 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.45 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Petkus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.